March 04, 2026

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

Conexiant

February 23, 2026

Rapunzel Syndrome Masks Weight Loss

Researchers identify an extensive trichobezoar in a child with progressive weight loss and feeding changes.

Conexiant

February 19, 2026

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

Conexiant

February 20, 2026

Ethosuximide vs Placebo for IBS Pain

Randomized trial found no improvement in abdominal pain and higher discontinuation rates with the calcium channel blocker.

Conexiant

February 19, 2026

Proton Pump Inhibitors and Cancer Risk

Investigators evaluate cancer risk tied to extended acid suppression therapy.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 18, 2026

Medical Oddities: Essential Oil, Deadly Consequences

A cabinet mix-up, a chatty heart, a violet catheter bag, stressed kids, and tea that won’t save the brain—just another week.

Conexiant

January 27, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Conexiant

November 12, 2024

Gut Bacteria Linked to Insulin Resistance

Study highlights how 'Proteobacteria and bile acids in the gut negatively impact insulin sensitivity,' offering potential therapeutic targets across the microbiome-gut-adipose-liver axis.

Conexiant

November 18, 2024

The Adaptive Immune System's Role in Gut Health and IBD

Researchers identified segment-specific effects of immune cells on intestinal contractions, providing new angles for managing inflammatory bowel disease.

Conexiant